SNY Sep 2024 45.000 call
| Previous close | 13.60 |
| Open | 13.60 |
| Bid | 10.00 |
| Ask | 14.30 |
| Strike | 45.00 |
| Expiry date | 2024-09-20 |
| Day's range | 13.60 - 13.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 36 |
Investor's Business DailyNovavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
GlobeNewswireDupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps Dupixent is the leading biologic medicine for all five FDA-approved indications in new-to-brand prescriptions TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the
BloombergCD&R in Talks With Banks Over Debt to Fund Equity for Sanofi Arm
(Bloomberg) -- Clayton Dubilier & Rice is discussing the possibility of using borrowed money to fund a part of the equity check in its bid for Sanofi’s €15 billion ($16.6 billion) consumer health division, according to people familiar with the matter.Most Read from BloombergHousing’s Worst Crisis in Decades Reverberates Through 2024 RaceFrom Louisville, a Push to Plant Trees for Public HealthUS Driving and Congestion Rates Are Higher Than EverAn Affordable Nomadic Home Design Struggles to Adapt
